Settled
Do GLP-1 receptor agonists improve body weight & composition versus placebo?
Mostly studied in coronary & atherosclerotic disease. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Very likely. So far, repeated by independent trials.
NoUnsureYes
- Belief
- 0.91 (range 0.67–1.00)
- Trials for
- 59
- Trials against
- 6
- Inconclusive
- 11
Already under way
- GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE…NCT07588984 · not yet recruiting · started 2026
- Repositioning Omega-3 Fatty Acids For Treatment Of Glycaemia And Cardiometabolic DiseaseNCT07677995 · enrolling by invitation · started 2026
- Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome: A Multicentre,…NCT07770282 · not yet recruiting · started 2026
- OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management ProgrammeNCT07779343 · recruiting · started 2026
- A Randomized, Open-label, Clinical Trial Evaluating the Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease…NCT07254572 · recruiting · started 2025
The evidence so far
- Registered trials
- 653
- With posted results
- 228
- Published papers
- 63
Of 350 decided analyses: 210 favor glp-1 receptor agonists, 69 find no difference, 71 favor the comparator.
Papers
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.Trial report · 2024
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.Trial report · 2011
- HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.Trial report · 2014
- Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.Trial report · 2018
- The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.Trial report · 2021
- Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.Trial report · 2017
Trials
- Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up PeriodNCT01272232 · 23 posted results
- A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesNCT04867785 · 24 posted results
- Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up PeriodNCT00781937 · 12 posted results
- Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist SettingNCT02963935 · 15 posted results
- A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes MellitusNCT05048719 · 20 posted results
- A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 DiabetesNCT05564039 · 8 posted results
- Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.NCT03856047 · 16 posted results
- A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 DiabetesNCT03987919 · 6 posted results